Loading stock data…
Syndax Pharmaceuticals, Inc. (SNDX)
$19.94-0.62 (-3.02%)
Market ClosedLast close Sep 8
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Syndax Pharmaceuticals, Inc. in the Healthcare sector is trading at $19.94 with a market capitalization of $1.8B. Wall Street consensus targets $37.55 (11 analysts), implying a +88.3% move over the next 12 months. The stock is currently 22% below its 52-week high of $25.59, remaining 5.0% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +88.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $72.79M↑ | $64.86M↓ | $68.73M↑ | $45.87M↑ | $37.96M |
| Gross Profit | $69.58M↑ | $62.23M↓ | $66.02M↑ | $43.77M↑ | $36.68M |
| Operating Income | -$39.99M↓ | -$34.20M↑ | -$62.55M↓ | -$57.43M↑ | -$69.35M |
| Net Income | -$49.36M↓ | -$42.67M↑ | -$68.01M↓ | -$60.72M↑ | -$71.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R ac...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.84B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1462.12%
Volume
Today's trading volume
1.20M
Recent News
Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
With the third quarter well underway and most second-quarter earnings now in the rearview mirror, investors are starting to look ahead to the rest of 2026 and how best to position their portfolios. The good news is that the latest earnings season has given investors plenty to work with. According to FactSet, S&P 500 earnings are on track to rise about 50% year-over-year in the second quarter, which would mark the index’s strongest earnings growth since Q2 2021. Meanwhile, profit margins are on t
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?
Syndax Pharmaceuticals (NASDAQ:SNDX) just posted a quarter that nearly doubled revenue, yet shares slipped 2.41% anyway. On its August 4 earnings call, management reported combined sales of $115 million across its two approved drugs, both now annualizing above $200 million a year. So why didn’t the market cheer? The answer sits inside the details investors […]
Syndax (SNDX) Q2 2026 Earnings Call Transcript
Revenue surged 92% year-over-year to $72.8 million, driven by Revuforj and Niktimvo.
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors
Syndax Pharmaceuticals reported past second-quarter 2026 results with revenue rising to US$72.79 million from US$37.96 million, while net loss narrowed to US$49.36 million and basic loss per share improved to US$0.55 from US$0.83 a year earlier. An interesting takeaway is that six‑month revenue more than doubled to US$137.65 million as losses shrank materially, suggesting improving operating leverage as Revuforj and Niktimvo sales scale. We’ll now explore how this revenue acceleration and...
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ...
Syndax Pharmaceuticals Inc (SNDX) reports strong Q2 2026 results with combined product revenue reaching $115 million, despite fluctuations in new patient starts.